论文部分内容阅读
AIM: To prepare polylactic acid microspheres of Erythromycin for Lung targeting. METHEDS: The orthogonal test design was used to optimize the technology of preparation. The character of the microspheres, drug release in vitro, stability and tissue distribution were examined. RESULTS: The Erythromycin polylactic acid microspheres was regular in its morphology. Drug was enveloped in microspheres but not physically mixed with PDLLA. The average particle size was 11.65mm with over 94% of the microspheres being in the range of 5~20mm; The drug loading and the incorporation efficiency were 18% and 60% respectively. The microspheres were stable for three month at 4℃ and room temperature. The in vitro release properties could be expressed by the Higuchi抯 equation: y = 28.067 + 3.8515t1/2 (r = 0.9834). Comparing with injection, the drug in microspheres was more concentrated in lung tissue. CONCLUSION: Erythromycin polylactic acid microspheres showed significant sustained release and lung targeting.
AIM: To prepare polylactic acid microspheres of Erythromycin for Lung targeting. METHEDS: The orthogonal test design was used to optimize the technology of preparation. The character of the microspheres, drug release in vitro, stability and tissue distribution were examined. RESULTS: The Erythromycin The drug was enveloped in microspheres but not physically mixed with PDLLA. The average particle size was 11.65mm with over 94% of the microspheres being in the range of 5 ~ 20mm; The drug loading and the incorporation The in vitro release properties could be expressed by the Higuchi equation: y = 28.067 + 3.8515t1 / 2 (r = 0.9834) . Comparing with injection, the drug in microspheres was more concentrated in lung tissue. CONCLUSION: Erythromycin polylactic acid microspheres showed significant sustained release and lung t argeting.